R&D Pipeline

AiCuris has a broad R&D portfolio, with one compound in Phase 3 development (Letermovir, partnered to MSD), one compound currently in Phase 2 and five compounds in Phase I. Additional research projects in virology and bacteriology sustain a continuous and balanced pipeline of innovative drug candidates.